D&MD s hERG: Technology and Market Analysis Report is the only syndicated report that comprehensively addresses the hERG market landscape. The Report details the physiology and biology of hERG as well as its role in drug toxicity.
It focuses on the physiological functioning of the hERG channel, its blockade by drugs and precipitation of LQTS. In addition to describing the technical aspects of hERG, the Report presents a thorough market analysis complemented by primary data from a proprietary survey conducted on this topic by D&MD.
Chapter 1: Executive Summary
- Scope of This Report
- Why is hERG becoming so crucial in Drug Discovery and Development?
- What are the strategic opportunities in the hERG marketplace?
- Summary of hERG as a Toxicity Marker for Drug Discovery and Development and the Associated Market Opportunity
Chapter 2: hERG - The Channel, Its Physiological Role, and Drug Toxicity
- Scope of This Chapter
- Long QT Syndrome (LQTS) and Torsades de Pointes
- Biology of hERG and its Role in QT Prolongation
- hERG: A Promiscuous Target for Drug Interactions
- Molecular Modeling of hERG: Predictive In silico Modeling for hERG Channel
- Blockers and Features-Motifs of hERG Rendering it Promiscuous
- Affecting the Biological Function of hERG Other than by Blocking its Channel with Drugs
- In Conclusion- hERG and Drug-induced LQTS
Chapter 3: Experimental Approaches for Screening hERG
- Scope of This Chapter
- What is the experimental problem that needs to be addressed?
- Requirements for hERG Toxicity Screening
- In vitro and in vivo Approaches to hERG Channel Screening
Chapter 4: Market Analysis of the hERG Space
- Scope of This Chapter
- End-User Survey: Data and Analysis
- Quantitative Market Opportunity and Market Model
Chapter 5: Company Pro.les
- Scope of This Chapter
- Aurora Biomed
- AVIVA Biosciences Corporation
- Cellular Dynamics International
- CEREP
- ChanTest
- CreaCell
- Cyprotex
- Cytomyx Ltd.
- Flyion GmbH
- MDS Pharma Services
- Molecular Devices Corporation
- Neurion Pharmaceuticals, Inc
- Quintiles Transnational Corp
- Sophion Bioscience A/S
Appendix I: Drugs Inducing Torsades de Pointes (TdP)
Appendix II: Industry Presentation of Biological Properties, Market Landscape, and Regulatory Guidelines of hERG
TABLE OF EXHIBITS
- Exhibit 1.1 High Pro.le Drug Withdrawals from the Marketplace
- Exhibit 2.1 Normal Cardia Cycle (EKG)
- Exhibit 2.2 Long QT Syndrome and Torsades de Pointes
- Exhibit 2.3 Various Currents Involved in the Cardiac Normal Rhythm
- Exhibit 2.4 Schematic Structure of the hERG Channel
- Exhibit 2.5 Schematic Structure of the hERG Channel Illustrating the Large Ligan-binding Pocket Lined with Aromatic Residues
- Exhibit 2.6 Drug Block of hERG Channels Expressed in HEK293 Cells
- Exhibit 2.7 Pharma Blockbusters Taken Off the Market Due to hERG Inference
- Exhibit 2.8 hERG Interacts with a Large Number of Drugs in Different Therapeutic Classes
- Exhibit 2.9 The Total IhERG (hERG current) Depends on a Number of Factors
- Exhibit 3.1 IKr current and QT Prolongation
- Exhibit 3.2 Requirements for Technology to be Adopted into the hERG Screening Marketplace
- Exhibit 3.3 A comparison of Technical Aspects of in vitro Approaches to Screen hERG K+ Channels
- Exhibit 4.1 Key Challenges in the hERG Marketplace
- Exhibit 4.2 Technology and Market Trends in the hERG Toxicity Screening Space
- Exhibit 4.3 Bottlenecks in the Toxicity Screening Space
- Exhibit 4.4 What are the Drivers for Deployment of hERG in Toxicity Screening Space?
- Exhibit 4.5 In terms of Market Opportunity, What % of Toxicity Screening Addresses hERG?
- Exhibit 4.6 Total Size of an hERG Screening Campaign within the Respondents Institution? - In terms of Assay Points per Week, Month, and Year
- Exhibit 4.7 Cost Per Assay Point that the Pharmaceutical Industry Currently Pays to Screen for hERG and what Fraction of hERG Screening is Outsourced
- Exhibit 4.8 All the Technologies Used for hERG Screening Mentioned by our Respondent Pool and Vendors in this Space
- Exhibit 4.9 What is the Future of hERG?
- Exhibit 4.10 Quantitative Market Model Presenting the Opportunity and Revenues in the hERG Marketplace
- Exhibit 4.11 Market Size for hERG Screening of Lead Compounds
- Exhibit 4.12 In-house Versus Outsourced hERG-based Toxicity Screening in Pharma and Biotech
- Exhibit 4.13 Market Opportunity for hERG-based Toxicity Screening Segregated via In-house Screening versus Outsourced Screening
- Exhibit 4.14 hERG-based Toxicity Screening: Product Sales and Fee-for-Service Offered by Vendors
